Pomerantz LLP is investigating whether Zevra Therapeutics and its executives engaged in securities fraud following a sharp stock price drop. The decline occurred after the European Medicines Agency's committee gave a negative opinion on Zevra's drug application for Niemann-Pick disease type C. This legal action could impact investors and the company's future regulatory efforts. Investors affected are encouraged to contact the law firm for potential class action participation.
Blade Resources has been approved to list its shares on the Canadian Securities Exchange, with trading starting around September 14, 2026. Prismo Metals owns 6,755,000 shares, representing about 24% of Blade, following a transaction involving the Hot...
Coinbase CEO Brian Armstrong predicts Bitcoin may reach $400,000 by 2030, a 420% increase from current levels, based on its four-year cycle pattern and recent market bottom. Key upcoming events like the CLARITY Act vote and the next Bitcoin halving s...
Ripple has upgraded its $1 billion-acquired Ripple Treasury platform by integrating GSmart AI agents to assist with liquidity management, cash flow forecasting, reconciliation, and risk assessment. These AI agents provide recommendations but require ...
Gemfields Group Limited held a commercial-quality emerald auction from August 24 to September 10, 2026, generating $29.6 million in sales. The auction achieved a record average price of $9.72 per carat, up from $7.46 in the previous sale, despite sel...
Pan African Resources has completed a feasibility study for its Soweto Tailings Retreatment project in South Africa, aiming to increase annual gold production at its Mogale complex to around 100,000 ounces. The project involves retreating tailings wi...
